From: Ceramide synthase 4 overexpression exerts oncogenic properties in breast cancer
Reactome_2022 Term | Overlap | P-value | Adjusted P-value | Odds ratio | Combined score |
---|---|---|---|---|---|
Innate Immune System R-HSA-168,249 | 100 (1035) | 1.80E − 12 | 2.36E-09 | 2.34569897 | 63.43460249 |
Immune System R-HSA-168,256 | 155 (1943) | 7.02E − 12 | 4.60E-09 | 1.940958578 | 49.846957 |
Cell Cycle, Mitotic R-HSA-69,278 | 60 (523) | 9.03E − 11 | 3.94E-08 | 2.781618301 | 64.33409133 |
Mitotic G1 Phase and G1/S Transition R-HSA-453,279 | 28 (147) | 1.55E − 10 | 5.09E-08 | 4.960806124 | 112.0443945 |
Cell Cycle R-HSA-1,640,170 | 68 (654) | 3.77E − 10 | 9.87E-08 | 2.497379682 | 54.19260145 |
Interleukin-4 and Interleukin-13 Signaling R-HSA-6,785,807 | 23 (107) | 5.57E − 10 | 1.22E-07 | 5.751514433 | 122.5517755 |
G1/S Transition R-HSA-69,206 | 25 (129) | 1.02E − 09 | 1.90E-07 | 5.055272471 | 104.6787947 |
G1/S-Specific Transcription R-HSA-69,205 | 12 (29) | 2.29E − 09 | 3.75E-07 | 14.70086789 | 292.4689634 |
NGF-Stimulated Transcription R-HSA-9,031,628 | 13 (39) | 1.11E − 08 | 1.35E-06 | 10.41958425 | 190.8686062 |